Erlotinib Achieved Partial Response in a Non-Small Cell Lung Cancer Patient with Gefitinib-Induced Interstitial Lung Disease

Publisher： Karger

E-ISSN： 1662-6575|4|3|464-466

ISSN： 1662-6575

Source： Case Reports in Oncology, Vol.4, Iss.3, 2011-09, pp. : 464-466

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Gefitinib-Induced Hepatotoxicity in Patients Treated for Non-Small Cell Lung Cancer

By  

Oncology Research and Treatment, Vol. 35, Iss. 9, 2012-08 ,pp. : 509-513

Karger

Access to resources Recommend Favorite

Erlotinib after Failure of Gefitinib Treatment of More Than 6 Months in Advanced Non-Small Cell Lung Cancer

By  

Oncology Research and Treatment, Vol. 35, Iss. 1-2, 2012-01 ,pp. : 8-9

Karger

Access to resources Recommend Favorite

Phase II Study of Gefitinib Readministration in Patients with Advanced Non-Small Cell Lung Cancer and Previous Response to Gefitinib

By  

Oncology, Vol. 79, Iss. 5-6, 2011-04 ,pp. : 423-429

Karger

Access to resources Recommend Favorite

Minocycline-Induced Hyperpigmentation in a Patient Treated with Erlotinib for Non-Small Cell Lung Adenocarcinoma

By  

Case Reports in Oncology, Vol. 10, Iss. 1, 2017-02 ,pp. : 156-160

Karger

Access to resources Recommend Favorite

Effectiveness of Erlotinib in Advanced Non-Small Cell Lung Cancer in Cases of Gefitinib Resistance after Treatment of More Than 6 Months

By  

Oncology Research and Treatment, Vol. 35, Iss. 1-2, 2012-01 ,pp. : 18-22

Karger

Access to resources Recommend Favorite